Phase I – Bioequivalence

295 trials 18 recruiting

Filter these 295 trials by condition, country, sponsor and more.

Open in Search →

Single-Dose Study in Healthy Participants to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One F… Recruiting

2026-526040-13-00 No medical condition. 2026-05-25
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Ponatin… Recruiting

2025-524311-37-00 chronic myeloid leukemia 2026-05-19
Bioequivalence clinical trial of two formulations of canagliflozin Recruiting

2026-525944-14-00 Healthy volunteers 2026-05-14
A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy Adults Recruiting

2025-525125-12-00 Migraine with or without aura 2026-05-05
A research study to compare blood levels of cagrilintide after multiple doses of different versions of cagrilintide in adults with overweigh… Recruiting

2025-521384-12-00 obesity 2026-04-27
A Study to Learn How Different Injector Pens Affect the Study Medicine Called Genotropin® (somatropin) Delivery and Taken Up Into the Blood … Recruiting

2026-525165-52-00 Growth hormone deficiency 2026-04-14
A Study to Evaluate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Xdivane versus Opdivo® in Patients with Resected Melanoma Recruiting

2025-522307-14-00 Melanoma 2026-01-19
A phase 1 glucose clamp trial investigating the bioequivalence of CVC-001 cartridge vs U.S.-Licensed Lantus® in healthy male volunteers Recruiting

2024-516472-15-00 Type 1 diabetes mellitus (healthy participants) 2026-01-06
Comparative Bioavailability of Levonorgestrel 52 mg Intrauterine System versus Mirena® in Healthy Pre-Menopausal, Non-Pregnant Female Partic… Recruiting

2025-523736-39-00 No medical condition. 2025-12-29
Study of Q702 in Subjects with Relapsed or Refractory Chronic Graft-versus-Host Disease (cGVHD) Recruiting

2025-522680-14-00 Chronic Graft-versus-Host Disease 2025-12-23
A Phase I double blinded, single-center, randomized, crossover study comparing the PK, PD, safety and tolerability of a single IV dose (1µg/… Recruiting

2024-518285-27-00 Not applicable (submitted trial is a bioequivalence stu 2025-12-01
A Phase I, randomized, consecutive dose, double blind, parallel study comparing the PK, PD, immunogenicity, safety and tolerability of LB-07… Recruiting

2024-518286-95-00 Not applicable (submitted trial is a bioequivalence stu 2025-07-02
Differences in absorption via oral route and via oral mucosa of hydrocortisone from 2-dimensionally printed dissolvable films in healthy vol… Recruiting

2024-517298-26-00 adrenal insufficiency 2025-05-21
Évaluation de la sécurité de l’embolisation par LipiodolⓇ dans l’arthrose digitale symptomatique réfractaire au traitement conventionnel : é… Recruiting

2024-513361-40-00 Arthrose digitale répondant aux critères de classificat 2024-12-05
Bio-equivalence of Rosuvastatin 10 mg Recruiting

2023-509661-21-00 Healthy volunteers 2024-10-03
Pharmacokinetics of inhaled levosimendan: a pilot study Recruiting

2024-514318-11-00 heart failure 2024-01-17
Phase I study of 225Ac-PSMA I&T in prostate cancer Recruiting

2024-513729-22-01 metastatic prostate cancer 2022-02-01
Multiple-dose, open-label, laboratory blinded, randomized, 2-period, 2-sequence, crossover, steady-state bioequivalence study comparing the … Ended

2026-526102-33-00 No medical condition 2026-05-11
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Maribav… Ended

2025-523487-21-00 cytomegalovirus (CMV) infection and/or disease that is 2026-05-05
Bioequivalence clinical trial of two formulations of loperamide. Ended

2026-525278-20-00 Healthy volunteers 2026-05-05
Multiple-Dose Study in Healthy Participants Under Fasting Conditions to Evaluate the Bioequivalence of One Film-Coated Mini-Tablet of Indapa… Ended

2026-525823-26-00 No medical condition. 2026-04-25
Multiple-Dose Bioequivalence of Mirabegron 50 mg Prolonged-Release Tablets in Healthy Participants Under Fasting Conditions. Ended

2025-522627-10-00 No medical condition. 2026-04-20
Bioequivalence of Mirabegron 50 mg Prolonged-Release Tablets in Healthy Participants Under Fed Conditions. Ended

2025-522624-27-00 No medical condition. 2026-04-15
A Study to Establish the Bioequivalence of Free Acid Tafamidis 61 mg Capsule and Tablet, and Evaluate the Safety and Tolerability of the 61 … Ended

2026-525342-29-00 Transthyretin amyloidosis 2026-03-16